Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Receivables Receivables - Accured Receivables - Affiliates Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Abvc Biopharma (ABVC) Raw Materials (2018 - 2019)

Abvc Biopharma (ABVC) has disclosed Raw Materials for 2 consecutive years, with $57904.0 as the latest value for Q4 2019.

For the quarter ending Q4 2019, Raw Materials rose 2.14% year-over-year to $57904.0, compared with a TTM value of $57904.0 through Dec 2019, up 2.14%, and an annual FY2019 reading of $57904.0, up 2.14% over the prior year.
Raw Materials was $57904.0 for Q4 2019 at Abvc Biopharma, up from $55835.0 in the prior quarter.
Across five years, Raw Materials topped out at $57904.0 in Q4 2019 and bottomed at $55824.0 in Q2 2019.